Clinical trial
Safety and Effectiveness of Three Anti-HIV Drugs Combined in One Pill (Trizivir)
NCT00004981 · Glaxo Wellcome, Industry · Unknown status
Key facts
| NCT number | NCT00004981 |
|---|---|
| Title | Safety and Effectiveness of Three Anti-HIV Drugs Combined in One Pill (Trizivir) |
| Official title | A Phase IIIB Randomized, Multicenter Study of the Efficacy and Safety of Combivir 1 Tablet Po Bid Plus Ziagen 300mg Po Bid Versus an Abacavir 300mg/Lamivudine 150mg/Zidovudine 300mg Combination Tablet Po Bid, Administered for 24 Weeks in Subjects With HIV-1 Infection |
| Lead sponsor | Glaxo Wellcome, Industry |
| Status | Unknown status |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | HIV Infections |
| Intervention type | Drug |
| Interventions | Abacavir sulfate, Lamivudine and Zidovudine, Lamivudine/Zidovudine |
| Enrollment | 230 |
| First posted | Aug 31, 2001 |
| Last update posted | Jun 24, 2005 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: